Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (11-20 of 266) with videos related to

Pageof 27
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 1, 2012
Castration-resistant metastatic prostate cancer: current status and treatment possibilitiesJoan Carles, Daniel Castellano, Miguel Ángel Climent, et al.
Molecular Metabolism|June 29, 2025
An epigenome atlas of mouse adipocytesLaura C Hinte, Adhideb Ghosh, Daniel Castellano-Castillo, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive reviewLucia Carril-Ajuria, Maria Cruz Martin-Soberón, Guillermo de Velasco, et al.
Cancer Metastasis Reviews|February 11, 2011
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Timothy Hobday, Daniel Castellano, et al.
Expert Review of Anticancer Therapy|January 21, 2017
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challengesJosé Luis González-Larriba, Pablo Maroto, Ignacio Durán, et al.
Oncoimmunology|March 8, 2021
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysisAlberto Carretero-González, Irene Otero, David Lora, et al.
Expert Opinion on Drug Safety|March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studiesSergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2014
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumorsDaniel Castellano, Enrique Grande, Juan Valle, et al.
Oncotarget|May 31, 2019
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trialsAlberto Carretero-González, David Lora, Ismael Ghanem, et al.
Biomedicines|March 25, 2022
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical TrialsRay Manneh, Mauricio Lema, Lucía Carril-Ajuria, et al.
Pageof 27

Showing results (11-20 of 266) with videos related to

Sort By:
Pageof 27
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 1, 2012
Castration-resistant metastatic prostate cancer: current status and treatment possibilitiesJoan Carles, Daniel Castellano, Miguel Ángel Climent, et al.
Molecular Metabolism|June 29, 2025
An epigenome atlas of mouse adipocytesLaura C Hinte, Adhideb Ghosh, Daniel Castellano-Castillo, et al.
Journal of Cancer Research and Clinical Oncology|January 22, 2022
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive reviewLucia Carril-Ajuria, Maria Cruz Martin-Soberón, Guillermo de Velasco, et al.
Cancer Metastasis Reviews|February 11, 2011
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Timothy Hobday, Daniel Castellano, et al.
Expert Review of Anticancer Therapy|January 21, 2017
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challengesJosé Luis González-Larriba, Pablo Maroto, Ignacio Durán, et al.
Oncoimmunology|March 8, 2021
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysisAlberto Carretero-González, Irene Otero, David Lora, et al.
Expert Opinion on Drug Safety|March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studiesSergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2014
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumorsDaniel Castellano, Enrique Grande, Juan Valle, et al.
Oncotarget|May 31, 2019
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trialsAlberto Carretero-González, David Lora, Ismael Ghanem, et al.
Biomedicines|March 25, 2022
Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical TrialsRay Manneh, Mauricio Lema, Lucía Carril-Ajuria, et al.
Pageof 27